Cargando…

Clinical benefits of FOLFOXIRI combined with bevacizumab for advanced-stage primary signet ring cell carcinoma of the appendix: A case report

Signet-ring cell carcinoma, which is an infrequent type of colorectal cancer. Abdominal pain is the primary presenting complaint of patients with acute appendicitis. It is difficult to diagnose patients with appendiceal carcinomas accompanying with symptoms of acute appendicitis. PATIENT CONCERNS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Nana, Lu, Yishan, Wang, Rui, Gao, Ping, Liu, Ge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402943/ https://www.ncbi.nlm.nih.gov/pubmed/37543827 http://dx.doi.org/10.1097/MD.0000000000034412

Ejemplares similares

A case report of anterior mediastinal signet ring cell carcinoma
por: Liu, Simin, et al.
Publicado: (2022)

NK cells adjuvant therapy shows survival benefits in a gastric mixed signet ring cell carcinoma patient: A case report
por: Jin, Yuan-Yuan, et al.
Publicado: (2021)

Occurrence of signet-ring cell carcinoma with cholangiocarcinoma 25 years after choledochal cyst excision: A case report
por: Zhang, Conggui, et al.
Publicado: (2018)

A nomogram for predicting the likelihood of lymph node metastasis in early gastric signet ring cell carcinoma: A single center retrospective analysis with external validation
por: Guo, Chun Guang, et al.
Publicado: (2016)

Primary signet ring cell carcinoma of the appendix mimicking acute appendicitis
por: Fusari, Mario, et al.
Publicado: (2012)

A rare case of signet ring cell carcinoma of the appendix
por: Caesar-Peterson, Shannon, et al.
Publicado: (2020)

Signet-ring cell carcinoma of the appendix with ganglioneuromatosis: a case report
por: Sato, Ayami, et al.
Publicado: (2022)

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
por: Xu, Wei, et al.
Publicado: (2016)

The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy
por: Yeom, Seung-Seop, et al.
Publicado: (2020)

Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis
por: Chen, Zhenguang, et al.
Publicado: (2015)

Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review
por: Özdirik, Burcin, et al.
Publicado: (2021)

Signet Ring Carcinoma of the Appendix Presenting as Crohn's Disease in a Young Male
por: Vukovic, Jonatan, et al.
Publicado: (2018)

Metastasis to the appendix from adenocarcinoma of the ascending colon: A case report
por: Li, Yingjie, et al.
Publicado: (2017)

Efficacy and safety of bevacizumab treatment for refractory brain edema: Case report
por: Meng, Xiangying, et al.
Publicado: (2017)

Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis
por: Kong, Ying, et al.
Publicado: (2021)

Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma
por: Tai, Cheng-Jeng, et al.
Publicado: (2016)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
por: Cervantes, A., et al.
Publicado: (2023)

Treatment response of bevacizumab combination chemotherapy in recurrent glioblastoma: A long-term retrospective study in Taiwan
por: Huang, Yu-Kai, et al.
Publicado: (2020)

Signet-ring cell carcinoma of the appendix: a case report with an emphasis on sonographic findings
por: Cho, Young Jong, et al.
Publicado: (2016)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study
por: Gao, Jie, et al.
Publicado: (2021)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy
por: Attademo, Laura, et al.
Publicado: (2018)

Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
por: Zhang, Ping, et al.
Publicado: (2018)

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review
por: Walter, H, et al.
Publicado: (2013)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review
por: Jing, Xu-Quan, et al.
Publicado: (2016)

Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study
por: Ma, Junxun, et al.
Publicado: (2015)

Tracheoesophageal fistula associated with bevacizumab after thoracic radiotherapy in non-small cell lung cancer: A case report
por: Zhang, Tao, et al.
Publicado: (2020)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report
por: Chen, Sixian, et al.
Publicado: (2021)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature
por: Ogata, Hideaki, et al.
Publicado: (2015)

Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab
por: Basso, Michele, et al.
Publicado: (2016)

Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition
por: Swed, Brandon, et al.
Publicado: (2021)

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
por: Huang, Chunlong, et al.
Publicado: (2021)

Feasibility of (125)I brachytherapy combined with arterial infusion chemotherapy in patients with advanced pancreatic cancer
por: Huang, Shujing, et al.
Publicado: (2023)

Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience
por: Marín-Pozo, Juan F., et al.
Publicado: (2016)

Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis
por: Ma, Hongbo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v8perm1f100tenbk2hsl3m5k5n